The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...

Cutaneous immune-related adverse events that develop after immune checkpoint inhibitor therapy become chronic in nearly ...

Swim Across America Grants $900,000 Toward First-of-Its-Kind Gene Editing Innovation. Two doctors will look to use this grant.

FDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer By Lori Solomon HealthDay Reporter TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...